Lilly to unveil new Foundayo, retatrutide, and eloraTZP data at EASD 2026 as it works to reshape cardiometabolic health treatment

Pivotal TRIUMPH-2 results showed retatrutide, an investigational triple hormone receptor agonist, produced substantial weight loss and A1C improvements in patients with obesity and type 2 diabetes

Findings from ACHIEVE-4, the largest and longest study of Foundayo conducted in type 2 diabetes, reaffirmed its safety profile and pointed to potential cardiovascular benefits

Lilly will unveil Phase 2 data for eloraTZP, its newest triple-acting medicine combining the selective amylin receptor agonist eloralintide with the GIP/GLP-1 receptor agonist tirzepatide

Eli Lilly and Company, maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), and Foundayo (orforglipron), will present new findings across its cardiometabolic health portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28 through October 2, 2026, in Milan, Italy. The data, spanning multiple mechanisms and treatment approaches, reflect the company’s ongoing effort to reshape the trajectory of cardiometabolic disease by broadening treatment options now while working to raise the future standard of care.

Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, said more than a billion people worldwide are living with diabetes or obesity, and meeting their varied needs requires multiple treatment approaches built on different mechanisms. He said Lilly has built its portfolio with the goal of changing the trajectory of the diabetes and obesity epidemics, and that at EASD 2026, the company is showing what the next generation of innovation could offer patients and how it intends to raise expectations for future medicines.

Lilly will also host an industry symposium titled Changing the Course of Cardiometabolic Disease on Monday, September 28, from 10:00 a.m. to 4:00 p.m. CEST, chaired by Prof. Rachel Batterham, senior vice president of medical innovation and external engagement at Lilly Cardiometabolic Health. Marking 150 years of innovation at Lilly, the program will examine how obesity and type 2 diabetes can be addressed from the earliest stages of disease, with sessions covering the growing role of oral therapies and the next generation of mechanisms with potential to reshape patient care.

Select Lilly presentations at EASD 2026

Retatrutide symposium | Wednesday, September 30, 2026 | 8:30 to 9:30 a.m. CEST
This EASD-sponsored symposium will present Phase 3 results for retatrutide, an investigational once-weekly triple receptor agonist targeting GIP, GLP-1, and glucagon.

TRIUMPH-2: Adults with obesity or overweight and type 2 diabetes taking retatrutide lost an average of up to 49.6 lbs (22.5 kg, or 20.8 percent) and reduced their A1C by an average of up to 1.6 percent at 80 weeks.

Mounjaro (tirzepatide) symposium | Wednesday, September 30, 2026 | 8:30 to 9:30 a.m. CEST
This EASD-sponsored symposium will present results for Mounjaro (tirzepatide) in adults with type 2 diabetes and established cardiovascular disease.

SURPASS-CVOT: Mounjaro demonstrated non-inferiority compared with Trulicity, showing an 8 percent lower risk of MACE-3 events (HR: 0.92; 95.3% CI: 0.83 to 1.01), while also delivering greater reductions in A1C and body weight among adults with type 2 diabetes and established cardiovascular disease.

EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST
This EASD-sponsored symposium on amylins in diabetes will feature Phase 2 results for eloraTZP, an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes.

Foundayo (orforglipron) symposium | Thursday, October 1, 2026 | 8:30 to 9:15 a.m. CEST
This EASD-sponsored symposium will present Phase 3 results for Foundayo (orforglipron) drawn from the ACHIEVE type 2 diabetes program.

ACHIEVE-4: Foundayo demonstrated non-inferiority compared with insulin glargine, showing a 16 percent lower risk of MACE-4 events (HR: 0.84; 95.0% CI: 0.59 to 1.20) and a 23 percent lower risk of MACE-3 events (HR: 0.77; 95.0% CI: 0.52 to 1.13) among adults with type 2 diabetes and obesity or overweight at elevated cardiovascular risk.

---

---

Related Topics and Keywords

EASD 2026, eloraTZP, Foundayo, Lilly, reshape cardiometabolic, retatrutide